Androgen Receptor And Its Coactivators In Prostate Cancer | 3120
Journal of Clinical & Experimental Pathology
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Amajor obstacle in the treatment of prostate cancer is the development of androgen-independent disease. We have recently
shown that Lef1, a transcription factor activated by WNT signaling, induced expression of the AR gene in androgen-
independent prostate cancer cell line, and consequently enhanced cell proliferation and invasion. This suggests that inhibition
Lef1 by blocking WNT signaling may represent a new therapeutic approach in combating androgen-independent prostate cancer.
While the majority of studies on AR focus on its action in epithelial cells, we are also examining the function of AR in prostate
stromal cells. We have shown, using an epithelial-stromal cell coculture system, that AR expression in stromal cells inhibits
prostate epithelial cell growth and invasion. We also found that androgen ablation prevented AR in the stroma from suppressing
epithelial growth and invasion. Therefore, the lack of stromal AR signaling may, in turn, facilitate the survival, growth, and
invasion of a sub-population of the epithelial prostate cancer cells, eventually leading to androgen-independence.
In addition to changes in AR expression, alterations in the level or splicing of AR coactivators could also contribute to
androgen-independent prostate cancer cell proliferation. Taken together, our findings lend new insights into the development of
androgen-independent prostate cancer and could lead to the development of novel therapies against the disease.
Dr. Lee is Professor in the Department of Pathology and Urology at New York University School of Medicine and Director of Molecular Pathology at New York Harbor Healthcare System and co-Director of Genetic Program, Center of Excellence of NYU Urological Disease. He obtained his MD degree from Beijing Medical University (Peking University, School of Medicine) and PhD from SUNY Downstate Medical Center. Dr. Lee was trained as a postdoctoral fellow with Dr. Robert Roeder at the Rockefeller University. Following his residency in Pathology at NYU Medical Center, he completed a Surgical/Oncologic Pathology fellowship at the University of Texas, M. D. Anderson Cancer Center. He is a specialized in Surgical, Oncologic, Genitourinary and Molecular Pathology. Dr. Lee is on editorial board for several peer reviewed journals.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals